Phototherapy achieves significant cost savings by the delay of drug based treatment in psoriasis

John Foerster (Lead / Corresponding author), Robert Dawe

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)
305 Downloads (Pure)


Background: Although used for decades in psoriasis, access to phototherapy is becoming increasingly restricted. Besides patient inconvenience, this is in large part to do with a perception of "high cost." We previously reported a comprehensive analysis of direct and indirect phototherapy treatment cost. However, no robust data exist on the actual savings associated with providing phototherapy in the treatment pathway.

Objectives: To quantify the cost savings achieved by phototherapy by delaying alternative treatments.

Methods: Costs accruing through the UK-wide established treatment pathway with and without phototherapy were analysed. Direct and indirectly incurred drug treatment costs were calculated using drug tariff, laboratory cost, estate rates and clinic review costs. To enhance reliability, ranges of cost scenarios were calculated by varying parameters such as drug dosing.

Results: Medium annual cost savings per patient were £2200 [range: £1800-£2900] for NB-UVB, and £3700 [range: £2500-£5300] if both NB-UVB and PUVA courses were administered, respectively. As the provider treated 656 ± 76 patients per year during the 6-year observational window, this amounted to savings of £Mio 2.4 [range: £Mio 1.6-£Mio 3.4], even excluding additional non-modelled drug-associated costs (eg diagnostics, adverse event management). Since we only consider cost savings by delay of drug treatment for the duration of phototherapy, drug price reductions through biosimilar introduction only have a small effect. We provide spreadsheets allowing adaptation cost savings projections by varying input variables.

Conclusions: Healthcare providers may achieve significant cost savings by implementing and/or widening access to phototherapy.

Original languageEnglish
Pages (from-to)90-96
Number of pages7
JournalPhotodermatology, Photoimmunology & Photomedicine
Issue number2
Early online date13 Sept 2019
Publication statusPublished - 19 Oct 2019


  • health economics
  • NB-UVB
  • psoriasis
  • treatment pathways

ASJC Scopus subject areas

  • Dermatology
  • Radiology Nuclear Medicine and imaging
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Phototherapy achieves significant cost savings by the delay of drug based treatment in psoriasis'. Together they form a unique fingerprint.

Cite this